Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from 'phenocopy' non-progressors

Dhamidhu Eratne^{a,b,c}

Michael Keem^{a,b}

Courtney Lewis^{a,b}

Matthew Kang^{a,b}

Mark Walterfang^{a,b,c}

Samantha Loi^{a,b}

Wendy Kelso^a

Claire Cadwallader^a

Samuel F Berkovic^d

Qiao-Xin Li^c

Colin L Masters^c

Steven Collins^c

Alexander Santillo^e

Dennis Velakoulis^{a,b}

The MiND Study Group

(The MiND Study Group Collaborators listed in Appendix 1)

a: Neuropsychiatry, Royal Melbourne Hospital, Parkville, VIC, Australia

b: Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia

c: National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia

d: Epilepsy Research Centre, Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia

d: Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute of Neuroscience and Mental Health and Department of Medicine, The University of Melbourne, Parkville, VIC, Australia

e: Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sölvegatan 18, Sweden

Corresponding author:

Dr Dhamidhu Eratne

BHB MBChB FRANZCP

Neuropsychiatry, Royal Melbourne Hospital, 300 Grattan St, Parkville VIC 3050, Australia

dhamidhu.eratne@mh.org.au

Tel: +61 3 9342 8750

Submission Type: Article

Title character count: 136

Abstract word count: 250

Number of references: 40

Number of figures: 3

Number of tables: 2

Word Count (excluding title page, abstract, references, figures and tables): 3202

Keywords:

ORCID iD

Dhamidhu Eratne: <https://orcid.org/0000-0002-3226-7645>

ACKNOWLEDGEMENTS AND FUNDING SOURCES

We are grateful for funding that supported this work: the Trisno Family Research Grant in Old Age Psychiatry, three NorthWestern Mental Health Research Seed Grants, MACH MRFF RART 2.1, and NHMRC (1185180). Finally, the authors would like to thank all the patients and their families for their participation.

The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

DECLARATION OF INTERESTS AND FINANCIAL DISCLOSURES

All the authors have nothing to disclose.

Statistical Analysis conducted by: Dr Dhamidhu Eratne and Dr Michael Keem

Abstract

Background:

Distinguishing behavioural variant frontotemporal dementia (bvFTD) from non-neurodegenerative 'non-progressor', 'phenocopy' mimics of frontal lobe dysfunction, can be one of the most challenging clinical dilemmas. A biomarker of neuronal injury, neurofilament light chain (NfL), could reduce misdiagnosis and delay.

Methods:

Cerebrospinal fluid (CSF) NfL, amyloid beta 1-42 (AB42), total and phosphorylated tau (T-tau, P-tau) levels were examined in patients with an initial diagnosis of bvFTD. Based on follow up information, patients were categorised as Progressors. Non-Progressors were subtyped in to Phenocopy Non-Progressors (non-neurological/neurodegenerative final diagnosis), and Static Non-Progressors (static deficits, not fully explained by non-neurological/neurodegenerative causes).

Results:

Forty-three patients were included: 20 Progressors, 23 Non-Progressors (15 Phenocopy, 8 Static), 20 controls. NfL concentrations were lower in Non-Progressors (Non-Progressors Mean, M=554pg/mL, 95%CI:[461, 675], Phenocopy Non-Progressors M=459pg/mL, 95%CI:[385, 539], Static Non-Progressors M=730pg/mL, 95%CI:[516, 940]), compared to bvFTD Progressors (M=2397pg/mL, 95%CI:[1607, 3332]). NfL distinguished Progressors from Non-Progressors with the highest accuracy (area under the curve 0.92, 90%/87% sensitivity/specificity, 86%/91% positive/negative predictive value, 88% accuracy). Static Non-Progressors tended to have higher T-tau and P-tau levels compared to Phenocopy Non-Progressors.

Conclusion:

This study demonstrated strong diagnostic utility of CSF NfL to distinguish bvFTD from phenocopy non-progressor variants, at baseline, with high accuracy, in a real-world clinical setting. This has important clinical implications, to improve outcomes for patients and clinicians facing this challenging clinical dilemma, as well as for healthcare services, and clinical trials. Further research is required to investigate heterogeneity within the non-progressor group and potential diagnostic algorithms, and prospective studies are underway assessing plasma NfL.

Introduction

Determining the underlying cause of cognitive and behavioural change associated with functional decline is often diagnostically challenging for clinicians. Even in centres with gold-standard multidisciplinary and multimodal investigations, individuals still face several years of diagnostic uncertainty, misdiagnosis, and delay. Diagnostic delay is greatest in patients with younger onset (symptom onset before 65 years) dementia who frequently present with psychiatric or behavioural symptoms [1–4]. In particular, the behavioural, personality and executive dysfunction symptoms of behavioural variant frontotemporal dementia (bvFTD) can be difficult to distinguish from primary psychiatric symptoms and other non-neurodegenerative causes of frontal lobe dysfunction [4–12].

An increasing body of literature has identified individuals who can appear clinically to have bvFTD, meet established diagnostic criteria for bvFTD, but who do not have the expected clinical, neuropsychological and neuroimaging progression over time. Various terms and definitions have been used for group, such as “bvFTD phenocopies”, “mild behavioural impairment”, and “non-progressors”, sometimes inconsistently, and a consensus has yet to be reached [13–18]. While people with a very slowly progressive bvFTD associated with the *C9orf72* genetic mutation have been identified [19–23], it is likely that this ‘non-progressors’ group is aetiologically heterogeneous, comprising people with primary psychiatric disorders or people with a mid-life stress related exacerbation of underlying personality, relationship or neurocognitive vulnerabilities. Regardless of the aetiology of phenocopy non-progressors, there is strong consensus that it is not benign, associated with high functional impact, patient distress and carer burden [13]. Differentiating between progressors and non-progressors at initial presentation, is challenging [11,15,18]. International consensus diagnostic criteria, which remain the gold standard for the diagnosis of bvFTD, involve diagnostic stratification into possible, probable or definite bvFTD [11,24]. Given that it can take years to reach a definitive diagnosis and the implications for treatment, prognosis, genetic counselling, and wider occupational and psychosocial outcomes, there is a critical need for earlier, accurate diagnostic differentiation. A biomarker that could assist in distinguishing between bvFTD progressors and non-progressors at baseline assessment could significantly improve outcomes for patients, their families, clinical trials, and healthcare systems.

Neurofilament light (NfL) is one of three subunits of a neuroaxonal cytoskeletal protein common to myelinated axons, with elevated levels in cerebrospinal fluid (CSF) and blood associated with neuronal injury and a marker of diagnosis, staging and prognosis, in a diverse range of neurological and neurodegenerative disorders [25–31]. Numerous studies have demonstrated elevated CSF and blood NfL in bvFTD compared to controls, as well as primary psychiatric disorders [29–38]. Recent expert consensus guidelines and recommendations have recommended NfL as a biomarker to assist with differentiating bvFTD from primary psychiatric disorders [11]. Our previous studies have demonstrated the ability for CSF NfL to distinguish bvFTD from primary psychiatric disorders, with high accuracy, in a real-world clinical setting, where patients who were ultimately diagnosed with a primary psychiatric illness were referred specifically for assessment of a possible neurodegenerative dementia [30] [Eratne et al., *Alzheimer's & Dementia*, in press, 2021].

To our knowledge, no studies have investigated the diagnostic utility of NfL to distinguish bvFTD from non-progressor phenocopy syndromes, where there was an initial clinical suspicion for and diagnosis of bvFTD, in real-world clinical settings. The primary aim of this study was to explore the diagnostic utility of CSF NfL in differentiating progressive (neurodegenerative) bvFTD from non-progressive syndromes that presented with behavioural, psychiatric, neurological, cognitive and functional impairments, and who met diagnostic criteria for at least possible bvFTD. Secondary aims included examining differences in clinical variables between diagnostic groups, and determining the diagnostic utility of NfL and other biomarkers in differentiating between possible subtypes of non-progressors.

Methods

This was a retrospective, longitudinal cohort study involving patients referred to Neuropsychiatry, The Royal Melbourne Hospital, a tertiary state-wide specialist service, for comprehensive multidisciplinary and multimodal diagnostic assessment of possible dementia, and ongoing management.

Inclusion criteria were: (1) A diagnosis of possible, probable or definite bvFTD [24] made at any time over the course of assessment with the service or follow-up, (2) CSF was collected as part of their

diagnostic work-up between June 2009 and December 2020, and remnant CSF was available for NfL analysis, (3) available formalised follow-up information for a minimum of 12 months.

Patients were assessed in inpatient and/or outpatient settings by a multidisciplinary team including neuropsychiatrists, neurologists, neuropsychologists, nurses, occupational therapists, speech pathologists, and social workers, as well as receiving multimodal investigations including brain MRI and SPECT/FDG-PET, and CSF analysis for Alzheimer's disease biomarkers. A consensus gold-standard diagnosis of possible, probable or definite bvFTD was made based on established diagnostic criteria [24]. With ongoing follow-up and longitudinal multidisciplinary assessments and multimodal investigations, this diagnosis could be revised as patients' conditions changed, and as new data was made available.

Patients' medical records were accessed, and data extracted included detailed demographic and clinical variables (Table 1), initial diagnosis, and most recent diagnosis based on serial assessments including obtaining follow up information from clinicians from other services. Structured symptom rating scales were not used consistently in clinical practice over the study period.

While acknowledging some of the issues with various current terminology and definition, for the purpose of this study we elected to use terminology commonly used in the literature and in clinical practice to describe the clinical phenotypes and progression over time – Progressors and Non-Progressors (Figure 1).

Progressors were defined as patients who were initially diagnosed with bvFTD, and retained the bvFTD diagnosis on follow up. In keeping with the retained bvFTD diagnosis on follow up, Progressors had either a) clear progression (clinical and/or neuroimaging and/or bedside cognitive/neuropsychological testing, and/or functioning), and/or b) their diagnostic classification strength progressed (i.e. from possible to probable, possible/probable to definite).

Non-Progressors were patients initially diagnosed with bvFTD, but who did not show evidence of progression on follow up (clinical and/or neuroimaging and/or bedside cognitive/neuropsychological testing, and/or functioning). To explore possible heterogeneity within the Non-Progressor Group, Non-

Progressors were further subtyped in to Phenocopy Non-Progressor, and Static Non-Progressor. Phenocopy Non-Progressors were defined as patients where the initial bvFTD diagnosis was eventually completely rescinded, a neurodegenerative disorder was deemed unlikely, and the final diagnosis was of one of a primary psychiatric / psychological / non-neurodegenerative disorder. Static Non-Progressors were patients where although there was no clear evidence of progression, there was a neurological/neurodegenerative cause was still suspected as the cause of static cognitive and functional impairments, and unlike the Phenocopy Non-Progressors, there was no clear primary psychiatric / psychological or non-neurodegenerative disorder diagnosis to fully explain the presentation. Two authors (Eratne, Keem) independently performed file reviews and categorisation. Data extraction and diagnostic categorisation was done blinded to NfL and other biomarker data.

CSF analysis has been previously described [30] [Eratne et al., *Alzheimer's & Dementia*, in press, 2021]. Briefly, all participants had CSF collected in a polypropylene tube during their initial assessment, analysed in duplicate for A β 42, T-tau and P-tau at the National Dementia Diagnostic Laboratory (NDDL), Melbourne, using INNOTEST ELISA (Fujirebio, Ghent, Belgium), remaining samples stored at -80°C. NfL was analysed at NDDL via NF-light ELISA (UmanDiagnostics, Umea, Sweden), according to the manufacturer protocols. Diluted CSF (1+1) and reconstituted standards were added to the plate in duplicate, incubated, washed. Samples displaying concentrations above the highest standard point were further diluted and re-assayed. Two internal controls of pooled CSF were included in each NfL plate. Mean intra-assay coefficient and inter-assay coefficient of variation was 6.2% and 11.3%, respectively.

Healthy control data was available from the 'Australian Imaging, Biomarker & Lifestyle' (AIBL) study, previously described [30]. Briefly, criteria for inclusion were: age at time of CSF sampling less than 70; no psychiatric or neurological diagnosis at time of CSF sampling nor in 18 months prior; negative amyloid PET; normal CSF A β 1-42, T-tau and P-tau levels; classification as healthy control based on formal neuropsychology assessment.

This study was approved by Human Research Ethics Committees at Melbourne Health (2016.038: approval for retrospective biomarker analyses; 2018.371, 2020.142: participants provided consent), and Florey Institute of Neurosciences and Mental Health (1648441.1).

Statistical analysis

Statistical analysis was undertaken using SPSS 27 and 28. General linear models (GLMs) were performed for comparison of NfL, A β 1-42, T-tau and P-tau in Progressors versus Non-Progressors, with age as a covariate. ROC curve analyses determined areas under the curve (AUC), Youden's method to determine optimal cut-off, sensitivity and specificity of biomarkers in distinguishing between groups. GLMs had bias-corrected and accelerated (BCa) confidence intervals (CIs) derived via nonparametric bootstrapping, 1000 replicates. Statistical significance was defined as any CI not capturing the null-hypothesis value (at the 95% level).

Results

Study cohort details and clinical variables (Table 1)

Forty-three patients met inclusion criteria: 20 bvFTD Progressors, and 23 Non-Progressors (comprising 15 Phenocopy Non-Progressors, 8 Static Non-Progressors). The mean age at initial assessment, age at CSF collection, age at onset, and proportion of females, were not significantly different between the patient groups. All patient groups had similar, several years of clinical follow up information available after the initial bvFTD diagnosis (mean 3 years). 20 controls were included, mean age 66 years.

Non-Progressors had a higher proportion of possible bvFTD at initial diagnosis, compared to Progressors (78% vs. 15%), and thus a lower proportion of probable bvFTD (22% vs. 85%). Several clinical variables were more frequent in all Non-Progressors, Phenocopy and Static Non-Progressors, compared to Progressors: substance use (approximately double in Non-Progressors), previous psychiatric diagnoses (close to 90% in Non-Progressors, versus 35% in Progressors), and non-psychotic psychiatric symptoms at presentation (over 80% in Non-Progressors, 60% in Progressors). New psychiatric symptoms (defined as within 5 years of presentation) were higher in Non-Progressors, particularly Phenocopy Non-Progressors (80% vs. 20% Progressors). All patients had functional impairment with low Global Assessment of Functioning (GAF) scores, and the majority of patients in all groups had abnormalities on neurological examination. All Progressors had abnormal

MRI (and almost all had abnormal SPECT/PET), and the majority of Non-Progressors had abnormalities on neuroimaging (although not always frontotemporal suggestive of bvFTD). All patient groups had similar impairments on the Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) bedside cognitive screening instrument total score and cognitive subdomains. Although Progressors had slightly poorer performance on the NUCOG total score and executive function domain, this was not statistically different. No patients, regardless of Progressor or Non-Progressor status, had normal performance on formal neuropsychological assessment.

CSF neurofilament light chain and other biomarkers

NfL concentrations were lower in Non-Progressors (Non-Progressors Mean, M=554pg/mL, 95%CI:[461, 675], Phenocopy Non-Progressors M=459pg/mL, 95%CI:[385, 539], Static Non-Progressors M=730pg/mL, 95%CI:[516, 940]), compared to bvFTD Progressors (M=2397pg/mL, 95%CI:[1607, 3332]) (Table 2 and Figure 2). Although lowest levels and the narrowest range was seen in the Phenocopy Non-Progressor group, levels were not statistically different to Static Non-Progressors (GLM mean difference, Mdiff=192, 95%CI:[124, 518]). The differences in NfL levels between Progressors and other groups were large: Progressors versus all Non-Progressors (GLM mean difference, Mdiff=1817, 95%CI:[988, 2745]), versus Phenocopy Non-Progressors (Mdiff=1885, 95%CI:[1093, 2721]), versus Static Non-Progressors (Mdiff=1694, 95%CI:[900, 2545]), and versus controls (Mdiff=2097, 95%CI:[982, 3290]).

T-tau levels were higher in Progressors (M=238pg/mL, 95%CI:[187, 298]) compared to Phenocopy Non-Progressors (M=127pg/mL, 95%CI:[96, 157], Mdiff=108, 95%CI:[44, 176]), but not Static Non-Progressors (M=273pg/mL, 95%CI:[178, 404]). Static Non-Progressors had higher T-tau levels than Phenocopy Non-Progressors (Mdiff=139, 95%CI:[26, 298]), Table 2, Supplementary Figure 1.

Static Non-Progressors also had higher P-tau levels than Phenocopy Non-Progressors (Mdiff=21, 95%CI:[3, 42]), Table 2, Supplementary Figure 2. A β 42 levels were lower in Phenocopy Non-Progressors compared to Static Non-Progressors (Mdiff=218, 95%CI:[77, 363]) and controls (Mdiff=170, 95%CI:[18, 300]), Table 2, Supplementary Figure 3. There were no sex differences in any biomarker levels.

NfL, T-tau, P-tau and A β 1-42 as diagnostic tests

NfL distinguished bvFTD Progressors from all Non-Progressors with the highest accuracy (area under the curve, AUC: 0.92, 90% sensitivity, 87% specificity at optimal cut-off of 726pg/mL), superior to T-tau (AUC 0.69, AUC difference 0.23, 95%CI:[0.09, 0.38], 72% sensitivity, 73% specificity, cut-off 192pg/mL), Figure 3 and Supplementary Material. NfL at the 726pg/mL cut-off distinguished ND from PSY with 86% positive predictive value (PPV), 91% negative predictive value (NPV), 6.8 positive likelihood ratio (LR+ve), 0.11 negative likely ratio (LR-ve), accurately classifying 88% (38/43) of patients.

NfL performed particularly well in distinguishing Progressors from Phenocopy Non-Progressors (AUC 0.99, 90% sensitivity, 100% specificity at cut-off of 726pg/mL, and at a cut-off of 583pg/mL, 100% sensitivity, 87% specificity, 100% PPV, 88% NPV, 0.10 LR-ve, 94% accuracy). NfL was once again superior to T-tau for this distinction (AUC difference 0.18, 95%CI:[0.02, 0.33]).

NfL had lower specificity in distinguishing Progressors from Static Non-Progressors (AUC 0.82, 90% sensitivity, 63% specificity, cut-off 716pg/mL). Combining NfL and A β 42 in to an NfL:A β 42 ratio resulted in improved AUC and specificity (AUC 0.88, 73% sensitivity, 100% specificity, cut-off 1.40), although this was not statistically significant (AUC difference 0.06, 95%CI:[-0.24, 0.11]). More information on these other comparisons are available in Supplementary Material.

Discussion

Our study found that baseline CSF NfL levels differentiated bvFTD from non-progressive 'phenocopies', with high accuracy, in a cohort of patients from a real-world clinical setting. Our findings have important clinical translation implications, supporting the use of CSF NfL, at initial assessment, as a sensitive and specific biomarker in predicting and distinguishing, progressive bvFTD from non-progressive and mimicking syndromes that have historically been subsumed under the 'phenocopy bvFTD' label. This is a common, challenging clinical dilemma, with patients often needing several years and multiple assessments and investigations before a phenocopy 'non-progressor' diagnosis can more confidently be made.

A novel aspect of our study was exploring Non-Progressors in more detail, given the likely heterogeneity within this group. We sub-categorised non-progressors in to 'Phenocopy Non-Progressors', where a primary psychiatric/psychological non-neurodegenerative formulation was ultimately made, compared to 'Static Non-Progressors', where there was still clinical suspicion of a neurological/neurodegenerative cause for static cognitive and functional impairments. There has been speculation that this group may still have neurodegenerative aetiology, subclinical, or at an extreme slowly progressive end of a bvFTD spectrum. Our findings in the Static Non-Progressor group, of slightly higher NfL, and in particular higher total tau levels, compared to the Phenocopy Non-Progressors, may be consistent with a subclinical bvFTD or another slowly progressive neurodegenerative or tau-related syndrome, albeit at a very low rate that is not demonstrated clearly on serial clinical and neuroimaging assessments. Interestingly, it was the Phenocopy Non-Progressor group that had lower AB42 levels, similar to levels seen in the bvFTD progressors. However, given the small number of Static Non-Progressors, caution is required in interpreting these exploratory findings. To help understand the possible heterogeneity in apparent non-progressors, further research in larger cohorts, with serial NfL levels, detailed clinical, biomarker, and genetic phenotyping, is warranted.

Our findings of overlap on a range of clinical variables at baseline, adds further weight to how challenging and complex the distinction between Progressors and Non-Progressors is, in real-world clinical practice. Bedside cognitive testing did not discriminate Progressors from Non-Progressors, and bvFTD Progressors had memory as well as executive function impairments. All Non-Progressors had impairments on neuropsychological assessment, and most Non-Progressors had abnormalities on structural and functional neuroimaging. These results, and our finding that Non-Progressors were more likely to only initially meet criteria for possible bvFTD, support other evidence on the greater uncertainty and diagnostic instability of possible bvFTD compared to probable/definite, and recommendations to be cautious about a diagnosis of bvFTD in the absence of neuroimaging changes consistent with bvFTD [11,14,18]. However, a significant proportion of Phenocopy Non-Progressors (33%, 5/15) had frontotemporal imaging changes that led to initially meeting criteria for probable bvFTD. Our findings would support increased suspicion of Non-Progressor in patients with a previous psychiatric history, and where psychiatric symptoms (separate to behavioural change) are

more prominent features at presentation. However, while there some differences at group levels, similar to what has been described in the literature [11,13,15,39], given the complexity and overlap between patient groups, no single clinical variable nor combination variables separated Progressors from Non-Progressors, as well as a single biomarker, NfL.

Our data supports an emerging consensus in the literature [10] that bvFTD phenocopies – represented predominately by our Phenocopy Non-Progressors – may be considered a ‘pseudodementia’ syndrome with several common factors: male sex, personality vulnerabilities, significant social stressors that may injure self-identity, maladaptive coping strategies including significant substance misuse, chronic dysthymia or ‘reactive’ depression, and for some, the additional development of melancholic depressive features to constitute a ‘double depression’. The majority of Non-Progressors in our cohort had a longstanding history of psychiatric symptoms (most commonly both non-melancholic/‘reactive’ and melancholic depressive symptoms), psychiatric history (typically major depressive disorder, PTSD), and Cluster B (especially borderline, histrionic and narcissistic) and Cluster C (primarily dependent and avoidant) personality constructs. Non-Progressors were more likely to have additional, new/superimposed symptoms, on this background, manifesting in context of interpersonal and psychosocial difficulties. In contrast, Static Non-Progressors did not have elevated rates of new psychiatric symptoms, but did have high rates of previous psychiatric diagnoses, and psychiatric symptoms at presentation, similar to Phenocopy Non-Progressors.

While this study is limited by its relatively small cohort size, our total case numbers were superior or comparable to several other retrospective cohort studies [13,14,16,17], and contribute to the limited literature in this area, in particular regarding biomarkers. The retrospective design is an inherent limitation, mitigated by the consistency of multidisciplinary and multimodal assessments within a single tertiary service, and rigorous file review blinded to biomarkers and conducted by two investigators separately. Although our cohort had several years of follow up and serial, gold-standard multidisciplinary and multimodal assessments and diagnosis based on established diagnostic criteria, it is possible that longer follow up could have revealed more insights, and most patients lacked definitive genetic or pathological confirmation. We did not have phonemic fluency data on participants, which is a limitation of the NUCOG and our dataset, given other studies have found discriminatory potential [39]. The complexity of those patients with multifaceted symptomatology, comorbidities and

psychiatric histories included in this study that warranted referral to a tertiary neuropsychiatry service for assessment and diagnosis, may not necessarily be generalisable to other services. However, most such patients are seen within less sub-specialised services nor do most patients have access to such tertiary services, and in addition the broad inclusion criteria of this study helped mitigate this possibility, and is a key strength relative to much of the literature.

This study demonstrated the diagnostic utility of CSF NfL in distinguishing progressive bvFTD from non-progressive variants and mimics, at baseline, with high accuracy. As blood NfL correlates strongly with CSF levels [25,40], a simple blood test as a first-tier test at initial assessment could strongly support the diagnosis of progressive bvFTD, versus phenocopy or mimicking syndromes. This would be of immense benefit in primary and secondary, and rural healthcare settings where the resources and expertise required to reach a gold-standard consensus diagnosis of bvFTD are often unavailable. With further study, a speculative diagnostic algorithm incorporating CSF NfL, other biomarkers, and clinical variables, could be developed to not only accurately differentiate bvFTD from non-progressive variants, but further delineate truly non-neurodegenerative from other aetiologies (Supplementary Material). The capacity to accurately diagnose a progressive neurodegenerative illness and identify a potentially reversible condition mimicking bvFTD at time of initial assessment, could dramatically reduce delay and misdiagnosis, and improve outcomes for patients, their families, and healthcare systems. NfL, supplemented by T-tau and A β 1-42, promises to transform complex diagnosis and prognostication in the highly vulnerable cohort of patients presenting with frontotemporal neuropsychiatric impairments, and building on these findings, larger prospective studies assessing CSF and plasma biomarkers, are underway.

References

- 1 Loi SM, Goh AMY, Mocellin R, *et al.* Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. *International Psychogeriatrics* Published Online First: 2020. doi:10.1017/S1041610220001489
- 2 Draper B, Cations M, White F, *et al.* Time to diagnosis in young-onset dementia and its determinants: the INSPIRED study. *International Journal of Geriatric Psychiatry* 2016;**31**:1217–24. doi:10.1002/gps.4430
- 3 Bradford A, Kunik ME, Schulz P, *et al.* Missed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors. *Alzheimer Disease & Associated Disorders* 2009;**23**:306–14. doi:10.1097/WAD.0b013e3181a6bebc
- 4 Woolley JD, Khan BK, Murthy NK, *et al.* The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: Rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. *Journal of Clinical Psychiatry* 2011;**72**:126–33. doi:10.4088/JCP.10m06382oli
- 5 Dols A. Identifying Specific Clinical Symptoms of Behavioral Variant Frontotemporal Dementia Versus Differential Psychiatric Disorders in Patients Presenting With a Late-Onset Frontal Lobe Syndrome. *Journal of clinical psychiatry* 2016;**77**:1189–200. doi:10.4088/JCP.15r10174
- 6 Vijverberg EGB, Gossink F, Krudop W, *et al.* The diagnostic challenge of the Late-onset frontal lobe syndrome: Clinical predictors for primary psychiatric disorders versus behavioral variant frontotemporal dementia. *Journal of Clinical Psychiatry* 2017;**78**:e1197–203. doi:10.4088/JCP.16m11078
- 7 Vijverberg EGB, Dols A, Krudop WA, *et al.* Diagnostic accuracy of the frontotemporal dementia consensus criteria in the late-onset frontal lobe syndrome. *Dementia and Geriatric Cognitive Disorders* 2016;**41**:210–9. doi:10.1159/000444849
- 8 Chan HM, Stolwyk R, Kelso W, *et al.* Comparing neurocognition in severe chronic schizophrenia and frontotemporal dementia. *Australian and New Zealand Journal of Psychiatry* Published Online First: 2014. doi:10.1177/0004867414529477
- 9 Velakoulis D, Walterfang M, Mocellin R, *et al.* Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: Clinicopathological series and review of cases. *British Journal of Psychiatry* 2009;**194**:298–305. doi:10.1192/bjp.bp.108.057034
- 10 Gossink FT, Dols A, Kerssens CJ, *et al.* Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry* 2016;**87**:64–8. doi:10.1136/jnnp-2014-308284
- 11 Ducharme S, Dols A, Laforce R, *et al.* Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. *Brain* 2020;**143**:1632–50. doi:10.1093/brain/awaa018
- 12 Tsoukra P, Velakoulis D, Wibawa P, *et al.* The Diagnostic Challenge of Young-Onset Dementia Syndromes and Primary Psychiatric Diseases: Results From a Retrospective 20-Year Cross-Sectional Study. *J Neuropsychiatry Clin Neurosci* 2021;:appineuropsych20100266. doi:10.1176/appi.neuropsych.20100266
- 13 Power C, Lawlor BA. The Behavioral Variant Frontotemporal Dementia Phenocopy Syndrome: A Review. *J Geriatr Psychiatry Neurol* 2021;**34**:196–208. doi:10.1177/0891988720924708
- 14 Power C, Hannigan O, Gibb M, *et al.* Phenocopy Frontotemporal Dementia: A Case Series from a National Memory Clinic and a Review of the Literature. *Eur psychiatr* 2017;**41**:S636–7. doi:10.1016/j.eurpsy.2017.01.1046

- 15 Hornberger M, Shelley BP, Kipps CMM, *et al.* Can progressive and non-progressive behavioural variant frontotemporal dementia be distinguished at presentation? *Journal of Neurology, Neurosurgery & Psychiatry* 2009;**80**:591–3. doi:10.1136/jnnp.2008.163873
- 16 Hornberger M, Piguet O, Kipps C, *et al.* Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia. *Neurology* 2008;**71**:1481–8. doi:10.1212/01.wnl.0000334299.72023.c8
- 17 Devenney E, Swinn T, Mioshi E, *et al.* The behavioural variant frontotemporal dementia phenocopy syndrome is a distinct entity - evidence from a longitudinal study. *BMC Neurology* 2018;**18**. doi:10.1186/s12883-018-1060-1
- 18 Devenney E, Bartley L, Hoon C, *et al.* Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study. *JAMA Neurology* 2015;**72**:1501–1501. doi:10.1001/jamaneurol.2015.2061
- 19 Brodtmann A, Cowie T, McLean C, *et al.* Phenocopy or variant: a longitudinal study of very slowly progressive frontotemporal dementia. *Case Reports* 2013;**2013**:bcr2012008077–bcr2012008077. doi:10.1136/bcr-2012-008077
- 20 Mattsson N, Rüetschi U, Pijnenburg YAL, *et al.* Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. *Molecular Medicine Reports* 2008;**1**:757–61. doi:10.3892/mmr-00000025
- 21 Meijboom R, Steketee RME, de Koning I, *et al.* Functional connectivity and microstructural white matter changes in phenocopy frontotemporal dementia. *European Radiology* 2017;**27**:1352–60. doi:10.1007/s00330-016-4490-4
- 22 Khan BK, Yokoyama JS, Takada LT, *et al.* Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. *Journal of Neurology, Neurosurgery & Psychiatry* 2012;**83**:358–64. doi:10.1136/jnnp-2011-301883
- 23 Devenney E, Foxe D, Dobson-Stone C, *et al.* Clinical heterogeneity of the C9orf72 genetic mutation in frontotemporal dementia. *Neurocase* 2015;**21**:535–41. doi:10.1080/13554794.2014.951058
- 24 Rascovsky K, Hodges JR, Knopman D, *et al.* Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;**134**:2456–77. doi:10.1093/brain/awr179
- 25 Khalil M, Teunissen CE, Otto M, *et al.* Neurofilaments as biomarkers in neurological disorders. *Nature Reviews Neurology* 2018;**14**:577–89. doi:10.1038/s41582-018-0058-z
- 26 Yuan A, Rao MV, Veeranna, *et al.* Neurofilaments and neurofilament proteins in health and disease. *Cold Spring Harbor Perspectives in Biology* 2017;**9**:1–24. doi:10.1101/cshperspect.a018309
- 27 Bridel C, van Wieringen WN, Zetterberg H, *et al.* Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA neurology* 2019;**76**:1035–48.
- 28 Gaetani L, Blennow K, Calabresi P, *et al.* Neurofilament light chain as a biomarker in neurological disorders. *Journal of Neurology, Neurosurgery & Psychiatry* 2019;**90**:870–81. doi:10.1136/jnnp-2018-320106
- 29 Ashton NJ, Janelidze S, Al Khleifat A, *et al.* A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun* 2021;**12**:3400. doi:10.1038/s41467-021-23620-z
- 30 Eratne D, Loi SM, Walia N, *et al.* A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists? *Australian and New Zealand Journal of Psychiatry* 2020;**54**:57–67. doi:10.1177/0004867419857811

- 31 Eratne D, Loi SM, Li QX, *et al.* Cerebrospinal fluid neurofilament light chain is elevated in Niemann–Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response. *Australian and New Zealand Journal of Psychiatry* 2020;**54**:648–9. doi:10.1177/0004867419893431
- 32 Skillback T, Farahmand B, Bartlett JW, *et al.* CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. *Neurology* 2014;**83**:1945–53. doi:10.1212/WNL.0000000000001015
- 33 Pijnenburg YAL, Janssen JC, Schoonenboom NSM, *et al.* CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer’s disease and controls. *Dementia and Geriatric Cognitive Disorders* 2007;**23**:225–30. doi:10.1159/000099473
- 34 Forgrave LM, Ma M, Best JR, *et al.* The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. *Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring* 2019;**11**:730–43. doi:10.1016/j.dadm.2019.08.009
- 35 Karantali E, Kazis D, Chatzikonstantinou S, *et al.* The role of neurofilament light chain in frontotemporal dementia: a meta-analysis. *Aging Clinical and Experimental Research* Published Online First: 2020. doi:10.1007/s40520-020-01554-8
- 36 Katisko K, Cajanus A, Jääskeläinen O, *et al.* Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. *Journal of Neurology* 2020;**267**:162–7. doi:10.1007/s00415-019-09567-8
- 37 Al Shweiki MR, Steinacker P, Oeckl P, *et al.* Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. *Journal of Psychiatric Research* 2019;**113**:137–40. doi:10.1016/j.jpsychires.2019.03.019
- 38 Eratne D, Janelidze S, Malpas CB, *et al.* Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. *Aust N Z J Psychiatry* 2021;;In Press. doi:10.1177/000486742111058684
- 39 Bussè C, Pettenuzzo I, Pompanin S, *et al.* Psychiatric Phenocopy Syndrome of Behavioral Frontotemporal Dementia: Behavioral and Cognitive Fingerprint. *J Alzheimers Dis* 2019;**72**:1159–64. doi:10.3233/JAD-190332
- 40 Wilke C, Preische O, Deuschle C, *et al.* Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. *Journal of Neurology, Neurosurgery & Psychiatry* 2016;**87**:1–4.

Figures and Tables

Figure 1. Diagnostic categorisation process

Progressors were patients initially diagnosed with bvFTD, who had progression over time (clinical and/or neuroimaging and/or bedside cognitive/neuropsychological testing, and/or functioning), and retained the bvFTD diagnosis on follow up. Non-Progressors were patients initially diagnosed with bvFTD, but who did not show evidence of progression on follow up (clinical and/or neuroimaging and/or bedside cognitive/neuropsychological testing, and/or functioning). Non-Progressors were further subtyped in to Phenocopy Non-Progressors (the initial bvFTD was eventually completely rescinded in favour of a primary psychiatric/psychological/non-neurodegenerative diagnosis), and Static Non-Progressors (although bvFTD was though less likely, there was still a suspicion of 'something neurological/neurodegenerative going on' to explain static cognitive and functional impairments)

Final diagnoses for Phenocopy Non-Progressors included: post-traumatic stress disorder, maladaptive personality traits/personality disorders, psychotic disorder, bipolar disorder, subjective cognitive complaints secondary to psychological/psychiatric/substance use issues. Final diagnoses for Static Non-Progressors included: dementia not-otherwise-specified, mild cognitive impairment (vascular, unspecified non-amnesic), mood and personality disorders as potentially contributing factors.

bvFTD, behavioural variant frontotemporal dementia; MCI, mild cognitive impairment; NOS, not otherwise specified

Table 1. Study population demographics and clinical information

	Progressor	Non-Progressor			
	bvFTD Progressor (n=20)	All Non-Progressors (n=23)	Phenocopy Non-Progressor (n=15)	Static Non-Progressor (n=8)	Controls (n=20)
Age at CSF	54 [50, 58]	53 [49, 56]	51 [46, 56]	56 [51, 60]	66 [65, 67]
Female	6 (30%)	5 (22%)	4 (27%)	1 (14%)	15 (75%)
Age at cognitive symptom onset	52 [48, 55]	50 [46, 54]	49 [44, 53]	52 [49, 57]	-
Duration cognitive/behavioural symptoms	3 [2, 4]	3 [2, 4]	3 [2, 4]	3 [1, 6]	-
Length of follow-up	3 [2, 4]	3 [2, 4]	3 [2, 4]	3 [2, 4]	-
Initial diagnosis possible bvFTD	3 (15%)	18 (78%)	10 (67%)	8 (100%)	-
Initial probable bvFTD	17 (85%)	5 (22%)	5 (33%)	0 (0%)	-
Final definite bvFTD^a	7 (35%)	-	-	-	-
GAF score	31-40	41-50	41-50	41-50	-
Substance use history	4 (20%)	10 (43%)	7 (47%)	3 (38%)	-
Previous psychiatric diagnosis, n (%)	7 (35%)	20 (87%)	13 (87%)	7 (88%)	-
Psychotic symptoms	(25%)	8 (35%)	6 (40%)	2 (25%)	-
Other psychiatric symptoms	12 (60%)	19 (83%)	12 (80%)	7 (88%)	-
New psychiatric symptoms (within 5 years)	4 (20%)	14 (61%)	12 (80%)	2 (25%)	-
MRI abnormal	20 (100%)	14 (64%)	10/14 (71% ^a)	4 (50%)	-
PET/SPECT	18/19 (95% ^a)	20/22 (91% ^a)	12/14 (86% ^a)	8(100%)	-

abnormal					
Neurological exam abnormal	14 (70%)	15 (65%)	9 (60%)	6 (75%)	-
Neuropsychology abnormal	20 (100%)	21/21 (100% ^a)	13/13 (100% ^a)	8 (100%)	-
NUCOG: total^b	70 [64, 76] (n=18)	77 [71, 82] (n=19)	74 [67, 81] (n=12)	81 [70, 90] (n=7)	-
NUCOG: attention	14 [12, 15]	15 [14, 16]	15 [14, 16]	15 [12, 18]	-
NUCOG: visuoconstruction	15 [14, 17]	17 [16, 18]	17 [15, 18]	18 [16, 20]	-
NUCOG: memory	14 [12, 16]	14 [12, 16]	14 [11, 15]	15 [13, 17]	-
NUCOG: executive	10 [8, 12]	13 [11, 15]	12 [9, 14]	14 [11, 17]	-
NUCOG: language	17 [15, 18]	18 [17, 19]	18 [16, 19]	18 [17, 20]	-

Unless otherwise stated, data is years [95% confidence interval], or n (%), at baseline/initial diagnosis of bvFTD. Values have been rounded to the nearest integer.

a: Genetic diagnoses: *C9orf72* (n=5), *MAPT* (n=2)

b: NUCOG is scored out of 100, with a cutoff of >80 for 'normal' cognitive function. Each constituent domains is scored out of 20.

bvFTD, behavioural variant frontotemporal dementia; CSF, cerebrospinal fluid; GAF, global assessment of functioning scale (lower scores indicate poorer functioning); Hx, history; NUCOG, Neuropsychiatry Unit Cognitive Assessment Tool.

Table 2. Cerebrospinal fluid biomarker concentrations in bvFTD Progressors, Non-Progressors, and controls

		Non-Progressors				
	bvFTD Progressors (n=20)	Non-Progressors Total (n=22)	bvFTD Phenocopy Non-Progressors (n=15)	Static Non-Progressors (n=8)	Controls (n=20)	Difference*
Group label	1	2	3	4	5	
CSF NfL	2397 [1607, 3332]	554 [461, 675]	459 [385, 539]	730 [516, 940]	523 [461, 588]	1>2,3,4,5
CSF T-tau	238 [187, 298] (n=18)	180 [135, 240] (n=22)	127 [96, 157] (n=14)	273 [178, 404]	182 [161, 203]	1>3; 4>3
CSF P-tau	38 [32, 46] (n=18)	40 [32, 51] (n=22)	32 [26, 40] (n=14)	54 [38, 77]	41 [37, 45]	4>3
CSF Aβ1-42	700 [587, 825] (n=18)	718 [637, 809] (n=22)	633 [536, 727] (n=14)	866 [754, 1026]	858 [814, 902]	4>3

Unless indicated, all values are means in pg/mL, with 95% bias-corrected and accelerated confidence intervals computed via bootstrapping with 1000 replicates. Values have been rounded to the nearest integer.

* details only differences in groups where general linear model mean difference confidence intervals do not capture the null hypothesis value

Aβ1-42, β-amyloid peptide 1-42; CSF: cerebrospinal fluid; NfL: neurofilament light chain protein; P-tau: phosphorylated tau; T-tau: total tau.

Figure 2. Box plot of cerebrospinal fluid (CSF) neurofilament light (NfL) between different groups.

bvFTD, behavioural variant frontotemporal dementia; CSF, cerebrospinal fluid; NfL, neurofilament light.

Figure 3. ROC Curve for behavioural variant frontotemporal dementia Progressors versus all Non-Progressors (comprising Phenocopy Non-Progressors and Static Non-Progressors)

ROC: receiver operating characteristic; NfL, neurofilament light; Aβ1-42, β-amyloid peptide 1-42; P-tau, phosphorylated tau; T-tau, total tau.

APPENDIX 1: Collaborators

Collaborators associated with The MiND Study Group:

Name	Affiliations (separated by semi colon)	Title
Christiane Stehmann	Australian National CJD Registry, The Florey Institute, Melbourne	Dr
Christopher Fowler	The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC	Dr
Parsa Ravanfar	Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia	Dr
Sarah Farrand	Neuropsychiatry, Royal Melbourne Hospital; Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne	Dr
Rosie Watson	Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia	A/Prof
Nawaf Yassi	Departments of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Australia Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia	A/Prof
Cath Kaylor-Hughes	Integrated Mental Health Team Dept of General Practice University of Melbourne, 780 Elizabeth St, Melbourne, 3010	Dr.
Richard Kanaan	Dept of Psychiatry, University of Melbourne, Austin Health, Heidelberg, VIC 3084	Prof.
Piero Perucca	Department of Medicine, Austin Health, The University of Melbourne; Comprehensive Epilepsy Program, Austin Health; Department of Neuroscience, Central Clinical School, Monash University; Department of Neurology, The Royal Melbourne Hospital; Department of Neurology, Alfred Health, Melbourne, VIC, Australia	A/Prof
Lucy Vivash	The Department of Neuroscience, The Central Clinical School, The Alfred Hospital, Monash University; and The Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia	Dr
Rashida Ali	Alfred Health; Monash University	Ms
Terence J. O'Brien	The Department of Neuroscience, The Central Clinical School, The Alfred Hospital, Monash University; and The Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia	Prof
Andrew Evans	Neuropsychiatry, Royal Melbourne Hospital	A/Prof
Anna King	The Wicking Dementia Centre, Tasmania	Professor
Patrick Kwan	Alfred Hospital; Monash University, Melbourne	Professor
Jane Gunn	Department of General Practice, The University of Melbourne	Professor
Ilias Goranitis	Health Economics Unit Centre for Health Policy Melbourne School of Population and Global Health, The University of Melbourne	Dr
Tianxin Pan	Health Economics Unit Centre for Health Policy Melbourne School of Population and Global Health, The University of Melbourne	Dr
Brett Trounson	The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC	Mr
Christos Pantelis	Melbourne Neuropsychiatry Centre & Department of Psychiatry, University of Melbourne, Parkville, VIC	Prof
Stefanie Colella	Neuropsychiatry, Royal Melbourne Hospital	Ms
Tomas Kalincik	Clinical Outcomes Research Unit (COrE), Department of Medicine, Department of Neurology, Royal Melbourne Hospital, Parkville, VIC, Australia	Prof
Charles B	Clinical Outcomes Research Unit (COrE), Department of Medicine,	Dr

Malpas	Department of Neurology, Royal Melbourne Hospital, Parkville, VIC, Australia	
Kaj Blennow	Clinical Neurochemistry Lab, Inst. of Neuroscience and Physiology University of Gothenburg, Sahlgrenska University Hospital, Mölndal Sweden	Prof
Henrik Zetterberg	Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China	Prof

Supplementary Material (see separate document)